Osimertinib plus platinum–pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study

BACKGROUND: The phase III FLAURA2 (NCT04035486) study will evaluate efficacy and safety of first-line osimertinib with platinum–pemetrexed chemotherapy versus osimertinib monotherapy in epidermal growth factor receptor mutation-positive (EGFRm) advanced/metastatic non-small-cell lung cancer (NSCLC)....

Descripción completa

Detalles Bibliográficos
Autores principales: Planchard, D., Feng, P.-H., Karaseva, N., Kim, S.-W., Kim, T.M., Lee, C.K., Poltoratskiy, A., Yanagitani, N., Marshall, R., Huang, X., Howarth, P., Jänne, P.A., Kobayashi, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453202/
https://www.ncbi.nlm.nih.gov/pubmed/34543864
http://dx.doi.org/10.1016/j.esmoop.2021.100271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453202/
https://www.ncbi.nlm.nih.gov/pubmed/34543864
http://dx.doi.org/10.1016/j.esmoop.2021.100271

Ejemplares similares